Cardiff Oncology Reports Positive Phase 2 Data for Onvansertib

Cardiff Oncology announced positive results from a Phase 2 clinical trial of its drug onvansertib. The company stated that these results support the efficacy and safety of the drug in certain cancer types. The study showed that onvansertib led to tumor shrinkage in patients, with manageable side effects. Cardiff Oncology emphasized that onvansertib could be a promising treatment option, particularly for cancers with KRAS mutations. In the Phase 2 study, the drug demonstrated meaningful clinical benefit in specific patient groups when used alone or in combination with other therapies. Company management noted that these results represent a significant milestone in the development program for onvansertib. Cardiff Oncology announced that it will begin discussions with regulatory authorities to advance the drug into further clinical trials. Investors should consider the drug's commercialization potential and competitive landscape when evaluating the impact of these positive data on the company's stock performance. Cardiff Oncology announced plans for studies in broader patient populations for onvansertib. This is not investment advice.